Holen Sie sich die Stockscreener-App
45.18
0.04%
-0.02
Handel nachbörslich:
45.18
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Soleno Therapeutics is Now Oversold (SLNO) - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.11 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Teachers Retirement System of The State of Kentucky Buys Shares of 13,001 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
State Street Corp Has $57.67 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
State Street Corp Buys 142,033 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewswire
Soleno Therapeutics Secures Massive $200M Financing Deal for Rare Disease Drug Development - StockTitan
When (SLNO) Moves Investors should Listen - Stock Traders Daily
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) & Pixie Dust Technologies (NASDAQ:PXDT) Head to Head Survey - Defense World
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape By Investing.com - Investing.com South Africa
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape - Investing.com
Wellington Management Group LLP Acquires 290,135 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
FDA delays approval decision until March on DCCR for excessive hunger in PWS - Prader-Willi Syndrome News
SLNO Crosses Below Key Moving Average Level - Nasdaq
Charles Schwab Investment Management Inc. Acquires 130,080 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Prader-Willi Syndrome Market Size, Share, Industry Growth, Key - openPR
Fmr LLC Acquires 665,363 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Where are the Opportunities in (SLNO) - Stock Traders Daily
Polar Asset Management Partners Inc. Has $1.60 Million Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
What is HC Wainwright’s Estimate for SLNO FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for SLNO FY2024 Earnings? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by Janus Henderson Group PLC - MarketBeat
HighVista Strategies LLC Makes New $560,000 Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Holocene Advisors LP Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Given “Outperform” Rating at Robert W. Baird - Defense World
Wainwright retains stock target, buy rating on Soleno amid FDA delay - Investing.com Nigeria
Wainwright retains stock target, buy rating on Soleno amid FDA delay By Investing.com - Investing.com South Africa
Outperform rating maintained on Soleno Therapeutics stock, regulatory approval outlook strong - Investing.com UK
Martingale Asset Management L P Purchases Shares of 21,975 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Short Interest Down 23.2% in November - MarketBeat
Baird maintains Outperform on Soleno, keeps $72 target By Investing.com - Investing.com Australia
Baird maintains Outperform on Soleno, keeps $72 target - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Vestal Point Capital LP - MarketBeat
Victory Capital Management Inc. Buys 2,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Receives FDA Extension for DCCR Review - Defense World
Soleno Therapeutics Inc (SLNO-Q) QuotePress Release - The Globe and Mail
PDUFA target action date for Soleno’s DCCR extended by three months - The Pharma Letter
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
FDA delays decision of Soleno’s Prader-Willi syndrome drug - Yahoo Finance
What the Options Market Tells Us About Soleno Therapeutics - Benzinga
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Wil - GuruFocus.com
FDA extends review of Soleno's Prader-Willi syndrome drug - Investing.com India
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment - Yahoo Finance
FDA extends review of Soleno's Prader-Willi syndrome drug By Investing.com - Investing.com Nigeria
Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment - Seeking Alpha
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - The Manila Times
Soleno Therapeutics Announces FDA Extension of Review - GlobeNewswire
Capnia stock soars to 52-week high, hits $60 milestone By Investing.com - Investing.com South Africa
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Buy” by Brokerages - Defense World
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):